NCT04633005View on ClinicalTrials.gov

Polypill Strategy for Heart Failure With Reduced Ejection Fraction

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

October 15, 2025

Study Completion Date

October 31, 2025

Conditions
Heart Failure
Interventions
DRUG

Polypill

Polypill formulation consisting of metoprolol succinate, empagliflozin, and spironolactone.

DRUG

Control Rx

Typical prescriptions of guideline-directed therapies for heart failure with reduced ejection fraction.

Trial Locations (1)

75209

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER